Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00692770




Registration number
NCT00692770
Ethics application status
Date submitted
5/06/2008
Date registered
6/06/2008
Date last updated
8/08/2018

Titles & IDs
Public title
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Scientific title
A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.
Secondary ID [1] 0 0
2008-001087-36
Secondary ID [2] 0 0
12414
Universal Trial Number (UTN)
Trial acronym
STORM
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Hepatocellular 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Liver

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Nexavar (Sorafenib, BAY43-9006)
Treatment: Drugs - Placebo

Experimental: Sorafenib (Nexavar, BAY43-9006) - Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)

Placebo comparator: Placebo - Participants received 2 tablets of placebo orally twice daily (BID)


Treatment: Drugs: Nexavar (Sorafenib, BAY43-9006)
Sorafenib 400 mg twice daily (BID)

Treatment: Drugs: Placebo
Placebo 2 tablets twice daily (BID)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Recurrence Free Survival (RFS) by Independent Assessment
Timepoint [1] 0 0
From randomization up to 4 years or until disease recurrence whichever came first
Secondary outcome [1] 0 0
Time to Recurrence (TTR) by Independent Assessment
Timepoint [1] 0 0
From randomization up to 4 years or until disease recurrence whichever came first
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
From randomization of the first subject until 4 years later.

Eligibility
Key inclusion criteria
* Subjects who have undergone surgical resection or local ablation (PEI or percutaneous or intraoperative RFA) for treatment of HCC with curative intent within 4 months from staging to potentially curative treatment. A maximum of 2 local ablation courses may be administered during this time period.
* At least 3 weeks (21 days) but no more than 7 weeks (49 days), from resection or last local ablation course, to CT/MRI scan date
* Male or female subjects >/= 18 years of age
* Confirmation of CR (absence of residual tumor after curative treatment), on the eligibility scan by independent radiological review.
* For subjects undergoing surgical resection pathology proven complete removal of tumor.
* Intermediate or High Risk of recurrence as assessed by tumor characteristics.
* Child-Pugh score 5 -7 points. A Child-Pugh score of 7 points is allowed only in the absence of ascites.
* ECOG Performance Status of 0.
* Adequate bone marrow, liver and renal function
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Recurrent HCC
* Child-Pugh score 7 points with presence of ascites.
* Low risk of recurrence after curative treatment
* History of cardiovascular disease
* History of HIV infection
* Active clinically serious infections (> grade 2 NCI-CTCAE version 3.0)
* Subjects with seizure disorder requiring medication (such as steroids or anti-epileptics)
* Subjects with evidence or history of bleeding diathesis
* Subjects undergoing renal dialysis
* Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry as defined by the signing of informed consent..
* Uncontrolled ascites (defined as not easily controlled with diuretic treatment)
* Encephalopathy
* History of GI bleeding within 30 days of randomization.
* Subjects with a history of esophageal varices bleeding which has not been followed by effective therapy and/or treatment to prevent bleeding recurrence.
* Prior anti cancer therapy for treatment of HCC (including sorafenib or any other molecular therapy) is excluded.
* Major surgery within 4 weeks of start of study as defined by the signing of informed consent, except for surgical resection or local ablation of HCC.
* Investigational drug therapy outside of this trial during or within 4 weeks of study entry, as defined by the signing of informed consent.
* Liver transplantation, this includes patients on a transplant list with the intention to transplant

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/08/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
28/11/2014
Sample size
Target
Accrual to date
Final
1114
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
- Camperdown
Recruitment hospital [2] 0 0
- Randwick
Recruitment hospital [3] 0 0
- Brisbane
Recruitment hospital [4] 0 0
- Heidelberg
Recruitment hospital [5] 0 0
- Melbourne
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
4120 - Brisbane
Recruitment postcode(s) [4] 0 0
3084 - Heidelberg
Recruitment postcode(s) [5] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Virginia
Country [20] 0 0
United States of America
State/province [20] 0 0
Washington
Country [21] 0 0
Argentina
State/province [21] 0 0
Buenos Aires
Country [22] 0 0
Argentina
State/province [22] 0 0
Ciudad Auton. De Buenos Aires
Country [23] 0 0
Argentina
State/province [23] 0 0
Santa Fe
Country [24] 0 0
Austria
State/province [24] 0 0
Innsbruck
Country [25] 0 0
Austria
State/province [25] 0 0
Linz
Country [26] 0 0
Austria
State/province [26] 0 0
Wien
Country [27] 0 0
Belgium
State/province [27] 0 0
Bruxelles - Brussel
Country [28] 0 0
Belgium
State/province [28] 0 0
Gent
Country [29] 0 0
Belgium
State/province [29] 0 0
Leuven
Country [30] 0 0
Belgium
State/province [30] 0 0
Liege
Country [31] 0 0
Brazil
State/province [31] 0 0
Rio Grande Do Sul
Country [32] 0 0
Brazil
State/province [32] 0 0
Sao Paulo
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Plovdiv
Country [34] 0 0
Bulgaria
State/province [34] 0 0
Varna
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
British Columbia
Country [37] 0 0
Canada
State/province [37] 0 0
Ontario
Country [38] 0 0
Chile
State/province [38] 0 0
Santiago
Country [39] 0 0
Chile
State/province [39] 0 0
Valparaíso
Country [40] 0 0
China
State/province [40] 0 0
Guangdong
Country [41] 0 0
China
State/province [41] 0 0
Guangxi
Country [42] 0 0
China
State/province [42] 0 0
Hubei
Country [43] 0 0
China
State/province [43] 0 0
Hunan
Country [44] 0 0
China
State/province [44] 0 0
Jiangsu
Country [45] 0 0
China
State/province [45] 0 0
Shanxi
Country [46] 0 0
China
State/province [46] 0 0
Sichuan
Country [47] 0 0
China
State/province [47] 0 0
Beijing
Country [48] 0 0
China
State/province [48] 0 0
Beijng
Country [49] 0 0
China
State/province [49] 0 0
Chongqing
Country [50] 0 0
China
State/province [50] 0 0
Dalian
Country [51] 0 0
China
State/province [51] 0 0
Hefei
Country [52] 0 0
China
State/province [52] 0 0
Shanghai
Country [53] 0 0
China
State/province [53] 0 0
Tianjin
Country [54] 0 0
France
State/province [54] 0 0
ANGERS cedex 09
Country [55] 0 0
France
State/province [55] 0 0
Bondy
Country [56] 0 0
France
State/province [56] 0 0
Bordeaux
Country [57] 0 0
France
State/province [57] 0 0
Creteil
Country [58] 0 0
France
State/province [58] 0 0
Lille
Country [59] 0 0
France
State/province [59] 0 0
Lyon
Country [60] 0 0
France
State/province [60] 0 0
Marseille
Country [61] 0 0
France
State/province [61] 0 0
Nice
Country [62] 0 0
France
State/province [62] 0 0
Paris
Country [63] 0 0
France
State/province [63] 0 0
Rennes
Country [64] 0 0
France
State/province [64] 0 0
Toulouse
Country [65] 0 0
France
State/province [65] 0 0
Vandoeuvre-les-nancy
Country [66] 0 0
France
State/province [66] 0 0
Villejuif
Country [67] 0 0
Germany
State/province [67] 0 0
Bayern
Country [68] 0 0
Germany
State/province [68] 0 0
Niedersachsen
Country [69] 0 0
Germany
State/province [69] 0 0
Nordrhein-Westfalen
Country [70] 0 0
Germany
State/province [70] 0 0
Rheinland-Pfalz
Country [71] 0 0
Germany
State/province [71] 0 0
Saarland
Country [72] 0 0
Germany
State/province [72] 0 0
Sachsen-Anhalt
Country [73] 0 0
Germany
State/province [73] 0 0
Berlin
Country [74] 0 0
Germany
State/province [74] 0 0
Hamburg
Country [75] 0 0
Greece
State/province [75] 0 0
Athens / Greece
Country [76] 0 0
Hong Kong
State/province [76] 0 0
Hong Kong
Country [77] 0 0
Hong Kong
State/province [77] 0 0
Kwun Tong
Country [78] 0 0
Hong Kong
State/province [78] 0 0
Shatin
Country [79] 0 0
Italy
State/province [79] 0 0
Campania
Country [80] 0 0
Italy
State/province [80] 0 0
Emilia-Romagna
Country [81] 0 0
Italy
State/province [81] 0 0
Lazio
Country [82] 0 0
Italy
State/province [82] 0 0
Lombardia
Country [83] 0 0
Italy
State/province [83] 0 0
Piemonte
Country [84] 0 0
Italy
State/province [84] 0 0
Puglia
Country [85] 0 0
Italy
State/province [85] 0 0
Sardegna
Country [86] 0 0
Italy
State/province [86] 0 0
Sicilia
Country [87] 0 0
Italy
State/province [87] 0 0
Veneto
Country [88] 0 0
Japan
State/province [88] 0 0
Chiba
Country [89] 0 0
Japan
State/province [89] 0 0
Ishikawa
Country [90] 0 0
Japan
State/province [90] 0 0
Kanagawa
Country [91] 0 0
Japan
State/province [91] 0 0
Osaka
Country [92] 0 0
Japan
State/province [92] 0 0
Tokyo
Country [93] 0 0
Japan
State/province [93] 0 0
Fukuoka
Country [94] 0 0
Japan
State/province [94] 0 0
Kumamoto
Country [95] 0 0
Japan
State/province [95] 0 0
Kyoto
Country [96] 0 0
Japan
State/province [96] 0 0
Okayama
Country [97] 0 0
Japan
State/province [97] 0 0
Tokushima
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Gyeonggido
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Seoul Teugbyeolsi
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Busan
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Daegu
Country [102] 0 0
Korea, Republic of
State/province [102] 0 0
Jeollabuk-do
Country [103] 0 0
Korea, Republic of
State/province [103] 0 0
Seoul
Country [104] 0 0
Mexico
State/province [104] 0 0
Distrito Federal
Country [105] 0 0
Mexico
State/province [105] 0 0
Nuevo Leon
Country [106] 0 0
Mexico
State/province [106] 0 0
México, D.F.
Country [107] 0 0
New Zealand
State/province [107] 0 0
Auckland
Country [108] 0 0
Portugal
State/province [108] 0 0
Coimbra
Country [109] 0 0
Romania
State/province [109] 0 0
Bucharest
Country [110] 0 0
Romania
State/province [110] 0 0
Cluj-Napoca
Country [111] 0 0
Romania
State/province [111] 0 0
Iasi
Country [112] 0 0
Russian Federation
State/province [112] 0 0
Moscow
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Obninsk
Country [114] 0 0
Russian Federation
State/province [114] 0 0
St. Petersburg
Country [115] 0 0
Singapore
State/province [115] 0 0
Singapore
Country [116] 0 0
Spain
State/province [116] 0 0
Asturias
Country [117] 0 0
Spain
State/province [117] 0 0
Barcelona
Country [118] 0 0
Spain
State/province [118] 0 0
Bilbao
Country [119] 0 0
Spain
State/province [119] 0 0
Catalunya
Country [120] 0 0
Spain
State/province [120] 0 0
Madrid
Country [121] 0 0
Spain
State/province [121] 0 0
Badajoz
Country [122] 0 0
Spain
State/province [122] 0 0
Córdoba
Country [123] 0 0
Spain
State/province [123] 0 0
Valladolid
Country [124] 0 0
Sweden
State/province [124] 0 0
Göteborg
Country [125] 0 0
Sweden
State/province [125] 0 0
Stockholm
Country [126] 0 0
Switzerland
State/province [126] 0 0
Bern
Country [127] 0 0
Switzerland
State/province [127] 0 0
Zürich
Country [128] 0 0
Taiwan
State/province [128] 0 0
Changhua
Country [129] 0 0
Taiwan
State/province [129] 0 0
Kaohsiung City
Country [130] 0 0
Taiwan
State/province [130] 0 0
Kaohsung
Country [131] 0 0
Taiwan
State/province [131] 0 0
Tainan
Country [132] 0 0
Taiwan
State/province [132] 0 0
Taipei
Country [133] 0 0
Taiwan
State/province [133] 0 0
Taoyuan
Country [134] 0 0
United Kingdom
State/province [134] 0 0
Hampshire
Country [135] 0 0
United Kingdom
State/province [135] 0 0
West Midlands
Country [136] 0 0
United Kingdom
State/province [136] 0 0
West Yorkshire
Country [137] 0 0
United Kingdom
State/province [137] 0 0
London
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Manchester
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Newcastle Upon Tyne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

TypeCitations or Other Details
Journal Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J... [More Details]

Results are available at https://clinicaltrials.gov/study/NCT00692770